Subgroup analysis of BR.21 demonstrated that 7% of non-squamous EGFR-wt NSCLC patients responded to erlotinib and 8% of elderly, EGFR status- unknown NSCLC patients responded to erlotinib [8, 9]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.